Lee’s Pharmaceutical Commences Phase I Clinical Trial for AI-Discovered HCC Drug AU409
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a leading biopharmaceutical company based in China, has announced...
Company
Roche’s Alzheimer’s Disease Diagnostic Kits Gain Approval in Hainan, Set for Use in Shanghai Ruijin Hospital
Swiss pharmaceutical and diagnostics giant Roche (SWX: ROG) has received approval from the Hainan Medical...
Mabwell Bioscience Secures Rights to Risen Pharmaceutical’s OA Treatment in Greater China
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a leading biopharmaceutical company in China, has entered...
Suzhou Zelgen’s Jacktinib Tablets Achieve Positive Results in Phase II IPF Clinical Trial
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...
ImmuneOnco Biopharmaceuticals Strikes Licensing Deal with Instil Bio for Global Rights to Dual-Targeted Antibodies
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has entered into a definitive licensing agreement with...
Sino Biopharmaceutical’s Benmelstobart Files for New Indication in China for Advanced RCC Treatment
Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced that...
AbbVie’s Allergan Aesthetics Wins NMPA Approval for Juvéderm Dermal Filler in China
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has secured marketing approval from China’s National...
Innovent Biologics’ Mazdutide NDA for Type 2 Diabetes Accepted for Review in China
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company in China, has announced that the...
GSK’s Jemperli Receives EC Approval for Endometrial Cancer Treatment in Combination Therapy
GSK plc (NYSE: GSK), a leading UK pharmaceutical company, has announced that the European Commission...
Fapon Biotech Expands Global Footprint with New IVD Manufacturing Facility in Indonesia
China-based in vitro diagnostic (IVD) company Fapon Biotech has announced a strategic investment with the...
Kyowa Kirin Revamps APAC Strategy, Exits China and Shifts R&D Focus
Japan’s pharmaceutical group Kyowa Kirin Co., Ltd (TYO: 4151) has announced a significant restructuring of...
Otsuka Pharmaceutical to Acquire US Biotech Jnana Therapeutics in $1.1 Billion Deal
Otsuka Pharmaceutical Co., Ltd, a leading Japanese pharmaceutical company, has announced the signing of a...
Sirnaomics Ltd Forms JV with Gore Range Capital to Pioneer Medical Aesthetics Innovations
Sirnaomics Ltd (HKG: 2257), a biopharmaceutical company specializing in RNAi therapeutics, has announced the formation...
MicroPort Scientific’s Bioabsorbable Stent System Gains NMPA Nod for Ischemic Heart Disease Treatment
Shanghai-based medical device conglomerate MicroPort Scientific Corp. (HKG: 0853) has announced that it has received...
HutchMed Reports 2024 H1 Financials with Mixed Results Amid Strategic Focus on R&D and Commercial Efficiency
China-based HutchMed (NASDAQ: HCM) has released its financial report for the first half of 2024,...
Tonghua Dongbao Pharmaceuticals Launches Phase III Clinical Trial for Semaglutide Biosimilar in China
Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has announced the commencement of a...
Biocytogen Strikes Licensing Deal with IDEAYA for Potential First-in-Class BsADC Program
China-based Biocytogen (HKG: 2315) has entered into an option and licensing agreement with US-based IDEAYA...
Pfizer Enters Multi-Year R&D Collaboration with Telescope Innovations to Leverage AI and Robotics
Pfizer Inc. (NYSE: PFE), a leading US pharmaceutical company, has entered into a multi-year collaborative...
GSK Reports Q2 2024 Earnings with 13% Growth, Vaccines Unit Sees Mixed Results
UK pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK, LON: GSK) has reported its financial results for...
Takeda Reports Q1 FY2024 Earnings with Growth in Key Therapies and New Launches
Japanese pharmaceutical company Takeda (TYO: 4502, NYSE: TAK) has announced its financial results for the...